TY - JOUR
T1 - Current and future strategies to monitor and manage coagulation in ECMO patients
AU - Zeibi Shirejini, Saeedreza
AU - Carberry, Josie
AU - McQuilten, Zoe K.
AU - Burrell, Aidan J.C.
AU - Gregory, Shaun D.
AU - Hagemeyer, Christoph E.
N1 - Funding Information:
SZS is supported by a Monash PhD scholarship. CEH is a Senior Research Fellow of the NHMRC of Australia (award number GNT1154270). SDG is the recipient of a Fellowship (102062) from the National Heart Foundation of Australia. AJCB is the recipient of an Emerging Leadership funding from the NHMRC Australia.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Extracorporeal membrane oxygenation (ECMO) can provide life-saving support for critically ill patients suffering severe respiratory and/or cardiac failure. However, thrombosis and bleeding remain common and complex problems to manage. Key causes of thrombosis in ECMO patients include blood contact to pro-thrombotic and non-physiological surfaces, as well as high shearing forces in the pump and membrane oxygenator. On the other hand, adverse effects of anticoagulant, thrombocytopenia, platelet dysfunction, acquired von Willebrand syndrome, and hyperfibrinolysis are all established as causes of bleeding. Finding safe and effective anticoagulants that balance thrombosis and bleeding risk remains challenging. This review highlights commonly used anticoagulants in ECMO, including their mechanism of action, monitoring methods, strengths and limitations. It further elaborates on existing anticoagulant monitoring strategies, indicating their target range, benefits and drawbacks. Finally, it introduces several highly novel approaches to real-time anticoagulation monitoring methods including sound, optical, fluorescent, and electrical measurement as well as their working principles and future directions for research.
AB - Extracorporeal membrane oxygenation (ECMO) can provide life-saving support for critically ill patients suffering severe respiratory and/or cardiac failure. However, thrombosis and bleeding remain common and complex problems to manage. Key causes of thrombosis in ECMO patients include blood contact to pro-thrombotic and non-physiological surfaces, as well as high shearing forces in the pump and membrane oxygenator. On the other hand, adverse effects of anticoagulant, thrombocytopenia, platelet dysfunction, acquired von Willebrand syndrome, and hyperfibrinolysis are all established as causes of bleeding. Finding safe and effective anticoagulants that balance thrombosis and bleeding risk remains challenging. This review highlights commonly used anticoagulants in ECMO, including their mechanism of action, monitoring methods, strengths and limitations. It further elaborates on existing anticoagulant monitoring strategies, indicating their target range, benefits and drawbacks. Finally, it introduces several highly novel approaches to real-time anticoagulation monitoring methods including sound, optical, fluorescent, and electrical measurement as well as their working principles and future directions for research.
KW - Anticoagulation
KW - Bleeding
KW - Extracorporeal Membrane Oxygenation
KW - Heparin-Induced Thrombocytopenia (HIT)
KW - Monitoring Techniques
KW - Respiratory Failure
KW - Thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85146854085&partnerID=8YFLogxK
U2 - 10.1186/s12959-023-00452-z
DO - 10.1186/s12959-023-00452-z
M3 - Review Article
C2 - 36703184
AN - SCOPUS:85146854085
SN - 1477-9560
VL - 21
JO - Thrombosis Journal
JF - Thrombosis Journal
IS - 1
M1 - 11
ER -